AYOXXA Biosystems GmbH, an international biotechnology company, is one of two industrial partners of EYE-RISK, a large biomedical consortium bringing together the expertise of ten renown scientific and clinical institutions and a patient organization from six European countries.

It is led by Prof. Dr. Marius Ueffing of the University Medical Center of Tübingen, Germany and Prof. Dr. Caroline Klaver of the Erasmus University Medical Center Rotterdam, Netherlands. AYOXXA contributes the LUNARIS™ technology platform to develop biomarker footprints to stratify patient subgroups.

The program is funded by the Horizon 2020 Research and Innovation Program of the European Union, aiming to study the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration (AMD), an incurable disease and leading cause of blindness in Western countries. The consortium had its kick-off meeting in June this year. The program is funded with 6 Mio. EUR until 2019.                     

EYE-RISK follows a multi-disciplinary approach exploiting epidemiological data and biosamples from large European eye cohorts and biobanks. Various risk factors including genes, environment, life style and age will be correlated with molecular data about pathways and drivers of AMD with the goal to improve diagnostics, to develop better therapies and to ultimately prevent blindness.          

“We are pleased to join this very prestigious expert network in EYE-RISK and are looking forward to developing assays to footprint specific biomarkers within large patient groups on our powerful LUNARIS™ protein multiplexing platform,” comments Dr. Markus Zumbansen, VP Research and Development at AYOXXA Biosystems GmbH. “With EYE-RISK, we follow our strategy to develop advanced ophthalmic diagnostic tools.”

Prof. Dr. Marius Ueffing adds: “We welcome AYOXXA as the expert in multiplex analysis in our consortium. We need faster protein testing solutions that generate more information out of precious samples without compromising data quality. EYE-RISK will bring a significant shift in our approach to the treatment of individuals suffering from AMD”.

more about AYOXXA biosystems